drugset / Trial / NCT07509892

A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

NCT07509892

Phase 2 Recruiting 198 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To assess the efficacy and safety of TQH3906 in treating systemic lupus erythematosus.

Timeline

Start
2026-06-22
Primary completion
2027-11
Completion
2028-03

Drugs

EvaluationDrugModalityDoseRoute
Subject TQH3906 Small molecule 16 mg Oral
Subject TQH3906 Small molecule 24 mg Oral